Table 5. Univariate analysis of OS and DFS in patients stratified by treatment modality.

Variables	Both pre and postoperative chemotherapy			Preoperative chemotherapy only
	P value for OS	P value for DFS		P value for OS	P value for DFS
Age	0.378	0.526		0.133	0.107
Gender	0.154	0.546		0.479	0.855
ASA risk score	0.209	0.115		0.116	0.014*
cT	0.913	0.316		0.180	0.031*
cN	0.448	0.239		0.281	0.479
NAC regimens	0.441	0.378		0.620	0.649
No. of NAC cycles	0.462	0.233		0.074	0.391
Clinical response	0.284	0.206		0.955	0.801
NISN	0.005*	0.035*		0.029*	0.116
Approach	0.066	0.061		0.426	0.734
Extent of gastrectomy	<0.001*	<0.001*		0.004*	0.019*
Additional organs resection	0.594	0.436		0.366	0.243
Tumor location	0.043*	0.014*		0.338	0.361
Differentiation	0.002*	<0.001*		0.018*	0.009*
LVI	0.018*	0.007*		0.087	0.052
Residual tumor	0.109	0.023*		0.135	0.002*
Postop complications	0.347	0.019*		0.057	0.241
HPR	0.310	0.085		0.052	0.107
pT category	<0.001*	<0.001*		0.016*	0.023*
pN category	0.019*	0.002*		0.007*	0.479
No. of postop cycles	0.020*	0.092		NA	NA

*, results are shown statistically significant. OS, overall survival; DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; ASA, American society of Anesthesiologists; NAC, neoadjuvant chemotherapy; LVI, lymphovascular invasion; HPR, histopathological response; postop, postoperative. NA, not available.